Cox regression model of OS for adult patients aged 20 years or older
| . | Variable . | Category . | n . | Events . | OM HR . | 99% CI . | P value . |
|---|---|---|---|---|---|---|---|
| Landmark model predicted by CD4 and IgA | |||||||
| Day 100 | |||||||
| CD4∗ | <104 × 106/L | 529 | 205 | 1.000 | — | .001 (2 df) | |
| >104 × 106/L, within 12 months after HCT | 1101 | 386 | 0.595 | 0.416-0.853 | <.001 | ||
| >104 × 106/L, after 12 months post-HCT | 1.031 | 0.772-1.376 | .788 | ||||
| Patient age, y | 1630 | 1.016 | 1.008-1.025 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 820 | 269 | 1.000 | — | <.001 (3 df) | |
| Acute leukemia advanced stage | 170 | 79 | 1.697 | 1.220-2.362 | <.001 | ||
| Acute leukemia unknown stage | 26 | 14 | 1.552 | 0.765-3.151 | .110 | ||
| MDS any stage | 614 | 229 | 1.105 | 0.865-1.411 | .295 | ||
| Steroid use | No | 943 | 302 | 1.000 | — | ||
| Yes | 687 | 289 | 1.379 | 1.114-1.708 | <.001 | ||
| Day 180 | |||||||
| CD4 and IgA levels | CD4, <115 × 106/L; IgA, <114 mg/dL | 156 | 68 | 1.000 | — | <.001 (3 df) | |
| CD4, <115 × 106/L; IgA, ≥114 mg/dL | 39 | 20 | 1.331 | 0.685-2.587 | .267 | ||
| CD4, ≥115 × 106/L; IgA, <114 mg/dL | 407 | 125 | 0.595 | 0.401-0.883 | .001 | ||
| CD4, ≥115 × 106/L; IgA, ≥114 mg/dL | 182 | 65 | 0.801 | 0.507-1.265 | .211 | ||
| Patient age, y | 784 | 1.021 | 1.008-1.033 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 419 | 137 | 1.000 | — | .006 (3 df) | |
| Acute leukemia advanced stage | 76 | 36 | 1.938 | 1.186-3.166 | .001 | ||
| Acute leukemia unknown stage | 14 | 5 | 0.847 | 0.260-2.757 | .717 | ||
| MDS any stage | 275 | 100 | 1.072 | 0.753-1.526 | .614 | ||
| Steroid use | No | 436 | 136 | 1.000 | — | ||
| Yes | 348 | 142 | 1.419 | 1.033-1.950 | .005 | ||
| Landmark model predicted by CD4 only at day 180 | |||||||
| CD4 count∗ | <115 × 106/L | 411 | 187 | 1.000 | — | <.001 (2 df) | |
| ≥115 × 106/L, within 10 months after HCT | 1184 | 380 | 0.318 | 0.205-0.493 | <.001 | ||
| ≥115 × 106/L, after 10 months post-HCT | 0.812 | 0.613-1.075 | .056 | ||||
| Patient age, y | 1595 | 1.016 | 1.008-1.026 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 804 | 260 | 1.000 | — | <.001 (3 df) | |
| Acute leukemia advanced stage | 167 | 76 | 1.746 | 1.246-2.446 | <.001 | ||
| Acute leukemia unknown stage | 24 | 12 | 1.376 | 0.642-2.949 | .281 | ||
| MDS any stage | 600 | 219 | 1.085 | 0.846-1.391 | .400 | ||
| Steroid use | No | 925 | 291 | 1.000 | — | ||
| Yes | 670 | 276 | 1.345 | 1.082-1.674 | <.001 |
| . | Variable . | Category . | n . | Events . | OM HR . | 99% CI . | P value . |
|---|---|---|---|---|---|---|---|
| Landmark model predicted by CD4 and IgA | |||||||
| Day 100 | |||||||
| CD4∗ | <104 × 106/L | 529 | 205 | 1.000 | — | .001 (2 df) | |
| >104 × 106/L, within 12 months after HCT | 1101 | 386 | 0.595 | 0.416-0.853 | <.001 | ||
| >104 × 106/L, after 12 months post-HCT | 1.031 | 0.772-1.376 | .788 | ||||
| Patient age, y | 1630 | 1.016 | 1.008-1.025 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 820 | 269 | 1.000 | — | <.001 (3 df) | |
| Acute leukemia advanced stage | 170 | 79 | 1.697 | 1.220-2.362 | <.001 | ||
| Acute leukemia unknown stage | 26 | 14 | 1.552 | 0.765-3.151 | .110 | ||
| MDS any stage | 614 | 229 | 1.105 | 0.865-1.411 | .295 | ||
| Steroid use | No | 943 | 302 | 1.000 | — | ||
| Yes | 687 | 289 | 1.379 | 1.114-1.708 | <.001 | ||
| Day 180 | |||||||
| CD4 and IgA levels | CD4, <115 × 106/L; IgA, <114 mg/dL | 156 | 68 | 1.000 | — | <.001 (3 df) | |
| CD4, <115 × 106/L; IgA, ≥114 mg/dL | 39 | 20 | 1.331 | 0.685-2.587 | .267 | ||
| CD4, ≥115 × 106/L; IgA, <114 mg/dL | 407 | 125 | 0.595 | 0.401-0.883 | .001 | ||
| CD4, ≥115 × 106/L; IgA, ≥114 mg/dL | 182 | 65 | 0.801 | 0.507-1.265 | .211 | ||
| Patient age, y | 784 | 1.021 | 1.008-1.033 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 419 | 137 | 1.000 | — | .006 (3 df) | |
| Acute leukemia advanced stage | 76 | 36 | 1.938 | 1.186-3.166 | .001 | ||
| Acute leukemia unknown stage | 14 | 5 | 0.847 | 0.260-2.757 | .717 | ||
| MDS any stage | 275 | 100 | 1.072 | 0.753-1.526 | .614 | ||
| Steroid use | No | 436 | 136 | 1.000 | — | ||
| Yes | 348 | 142 | 1.419 | 1.033-1.950 | .005 | ||
| Landmark model predicted by CD4 only at day 180 | |||||||
| CD4 count∗ | <115 × 106/L | 411 | 187 | 1.000 | — | <.001 (2 df) | |
| ≥115 × 106/L, within 10 months after HCT | 1184 | 380 | 0.318 | 0.205-0.493 | <.001 | ||
| ≥115 × 106/L, after 10 months post-HCT | 0.812 | 0.613-1.075 | .056 | ||||
| Patient age, y | 1595 | 1.016 | 1.008-1.026 | <.001 | |||
| Primary disease | Acute leukemia early or intermediate stage | 804 | 260 | 1.000 | — | <.001 (3 df) | |
| Acute leukemia advanced stage | 167 | 76 | 1.746 | 1.246-2.446 | <.001 | ||
| Acute leukemia unknown stage | 24 | 12 | 1.376 | 0.642-2.949 | .281 | ||
| MDS any stage | 600 | 219 | 1.085 | 0.846-1.391 | .400 | ||
| Steroid use | No | 925 | 291 | 1.000 | — | ||
| Yes | 670 | 276 | 1.345 | 1.082-1.674 | <.001 |
Evidence of nonproportional hazards was found by testing a time-dependent covariate for significance (P < .01). A piecewise proportional hazards model was constructed such that proportionality is not violated for the variable within each separate interval.